The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment

Pan Zhang(China Pharmaceutical University), Meirong Huo(China Pharmaceutical University), Xuxin Chu(China Pharmaceutical University), Xinyuan Zhou(Chinese Academy of Sciences), Yongwei Gu(Shanghai Medical College of Fudan University), Nan Liu(Nanfang Hospital), Fangnan Lv(China Pharmaceutical University), Jianping Zhou(China Pharmaceutical University), Lifang Yin(China Pharmaceutical University), Jiyong Liu(Fudan University Shanghai Cancer Center), Chao Qin(University of Southern California)
Biomaterials
April 12, 2022
Cited by 68


Related Papers